Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

E. I. du Pont de Nemours and Company

http://www.dupont.com/

Latest From E. I. du Pont de Nemours and Company

Korean Bioventure Financing Continues Downward Spiral In Q3

VC Investment in South Korea’s biopharma sector drops again as investors continue to shy away amid higher interest rates and reduced out-licensing deals.

South Korea Financing

Keeping Track: Furoscix, SPN-830 Show Difficulties Of Drug-Device Combinations

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Complete Response Letters

October Outlook For US FDA Approvals: Goal Dates Are Sparse, But Backlog Looms

Upcoming user fee goal dates include AstraZeneca’s tremelimumab, Amicus’ AT-GAA, and drug delivery technology-driven NDAs from Supernus/US Worldmeds and scPharmaceuticals

US FDA Performance Tracker Drug Review

Asia Deal Watch: Dong-A Brings In NeuroBo As Partner On Pair Of Cardiometabolic Candidates

Plus deals involving Takeda/Puma, SillaJen/Basilea, Celltrion/Abpro, METiS/Voronoi, Yuhan/AtoGen, Biocytogen/FineImmune and Avance/C3.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Diversified
  • Other Names / Subsidiaries
    • DowDuPont
    • DuPont
UsernamePublicRestriction

Register